由KRAS突变驱动的血管蛋白2在上皮癌中赋予了抗VEGF耐药性
Kayoko Hosaka1, Patrik Andersson1, Jieyu Wu1
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 171 65, Sweden.
概括
在上皮癌中KRAS突变会通过增加血管蛋白2 (ANG2) 增加抗VEGF药物的耐药性. 与抗VEGF和抗ANG2药物的联合治疗在这些瘤中显示出强大的抗癌作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 抗血管原药 (AADs) 在预测治疗效益和克服耐药性方面面临着挑战.
- 目前,没有可靠的生物标志物指导癌症患者的AAD治疗.
研究的目的:
- 研究具有KRAS突变的上皮癌中AAD耐药性的机制.
- 为了确定对抗AADs的KRAS突变癌症的潜在治疗策略.
主要方法:
- 研究了KRAS突变在调节 angiopoietin 2 (ANG2) 表达中的作用.
- 研究了ANG2对瘤血管新生和抗VEGF治疗的耐药性的影响.
- 在临床前模型中评估了与抗VEGF和抗ANG2药物联合治疗的疗效.
主要成果:
- 克拉斯突变对FOXC2进行上调,导致ANG2表达增加和VEGF独立的瘤血管生成.
- 具有KRAS突变的癌症对针对VEGF或ANG2的单一疗法表现出内在的耐药性.
- 与抗VEGF和抗ANG2药物的联合治疗在KRAS突变癌症中显示出协同作用的抗癌作用.
结论:
- KRAS突变作为抗VEGF治疗耐药性的预测标记.
- 针对VEGF和ANG2通路提供了一个有前途的治疗策略,用于KRAS突变的上皮癌.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mechanism of Angiogenesis
5.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K


